ISSUE 1433
| Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir (Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination with peginterferon and ribavirin for treatment of chronic HCV genotype 1 infection in adults with compensated liver disease. Telaprevir (Incivek) and boceprevir (Victrelis) were approved in 2011 for the same indication. Sofosbuvir (Sovaldi – Gilead), a nucleotide analog polymerase inhibitor that has been approved for use with and without interferon for treatment of multiple HCV genotypes, will be reviewed in the next issue of The Medical Letter.
STANDARD THERAPY — For many years, the standard therapy for chronic HCV genotype 1 infection (the most common genotype in the US and Europe) was 48 weeks of subcutaneously-injected
... more1. TJ Liang and MG Ghany. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368:1907.
2. Antiviral drugs. Treat Guidel Med Lett 2013; 11:19.
3. Drugs for hepatitis C. Med Lett Drugs Ther 2012; 54:81.
4. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
Would you like to read the rest of this issue? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
